Michael Imevbore, MD
Pulmonary Disease · New Haven, CTNPI 1679660021
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $278,068 of the $322,697 with a category attached, or 86.2%. GSK accounts for 65.2% of it on its own, with 35 other manufacturers making up the rest. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,168 payments — averaging $276.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$210K
- AstraZeneca$71K
- Sanofi$27K
- Novartis$5K
- Teva Pharmaceuticals USA, Inc.$2K
- Boehringer Ingelheim$2K
- plus $5K from 30 others
What the payments were for
- Consulting fees$5,3732%
- Speaking & faculty fees$278,06886%
- Travel & lodging$13,4734%
- Food & beverage$25,5848%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 386 | $210,416 |
| AstraZeneca | 305 | $70,539 |
| Sanofi | 59 | $27,400 |
| Novartis | 39 | $5,061 |
| Teva Pharmaceuticals USA, Inc. | 8 | $2,332 |
| Boehringer Ingelheim | 127 | $2,071 |
| Harmony Biosciences LLC | 24 | $521 |
| Genentech USA, Inc. | 23 | $495 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $484 |
| Mylan Specialty L.p. | 19 | $390 |
| Inspire Medical Systems, Inc. | 9 | $368 |
| Regeneron Healthcare Solutions, Inc. | 15 | $288 |
| Pfizer | 19 | $284 |
| Mallinckrodt Hospital Products Inc. | 13 | $236 |
| Amgen | 8 | $190 |
| Philips North America LLC | 10 | $149 |
| Jazz Pharmaceuticals Inc. | 7 | $147 |
| Grifols USA, LLC | 7 | $145 |
| Sunovion Pharmaceuticals Inc. | 27 | $135 |
| Electromed, Inc. | 6 | $118 |
| Insmed, Inc. | 5 | $117 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $113 |
| Actelion Pharmaceuticals US, Inc. | 4 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Advanced Respiratory, Inc | 3 | $84 |
| Johnson & Johnson | 4 | $69 |
| Shire North American Group Inc | 3 | $67 |
| Lilly USA, LLC | 2 | $61 |
| Baxter Healthcare | 2 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Optinose US, Inc. | 1 | $25 |
| Pulmonx Corporation | 1 | $23 |
| Covis Pharma GmbH | 1 | $21 |
| United Therapeutics Corporation | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$153,209
- FASENRA$60,367
- DUPIXENT$36,732
- AIRSUPRA$4,766
- XOLAIR$4,291
- CINQAIR$2,235
- ANORO$1,349
- BREZTRI$613
- GILENYA$485
- TEZSPIRE$483
- SYMBICORT$239
- Inspire Upper Airway Stimulation System$185
- BREZTRI AEROSPHERE$126
How this compares
$322,697 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,541 | $1,881,173 |
| FasenraBenralizumab | 180 | $1,068,779 |
| OfevNintedanib Esylate | 33 | $531,101 |
| Fasenra PenBenralizumab | 70 | $410,496 |
| XolairOmalizumab | 98 | $349,781 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 269 | $344,646 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 310 | $263,965 |
| TezspireTezepelumab-Ekko | 50 | $205,801 |
| NucalaMepolizumab | 28 | $168,369 |
| Breo ElliptaFluticasone/Vilanterol | 147 | $88,528 |
| Spiriva RespimatTiotropium Bromide | 53 | $54,920 |
| SymbicortBudesonide/Formoterol Fumarate | 81 | $34,540 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 55 | $34,439 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $34,231 |
| EliquisApixaban | 24 | $25,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $210,416 | $2,413,4792,046 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Tezspire, Symbicort | $70,539 | $1,653,766580 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $2,071 | $654,690185 claims |
| PfizerEliquis | $284 | $25,92524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Haven
- Geoffrey ChuppNew Haven$1.2M
- Naftali KaminskiNew Haven$180K
- Lauren CohnNew Haven$134K
- Erica HerzogNew Haven$74K
- Mridu GulatiNew Haven$53K
- Jennifer PossickNew Haven$48K
- Carolyn RochesterNew Haven$29K
- Maor SaulerNew Haven$18K
- Jonathan KoffNew Haven$15K
- Olurotimi AdekoluNew Haven$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.